Endovascular stenting using a sagittal sinus approach for sigmoid sinus wall dehiscence related to intractable pulsatile tinnitus: a case series.

BACKGROUND: Sigmoid sinus wall dehiscence can lead to pulsatile tinnitus with a significant decrease in quality of life, occasionally leading to psychiatric disorders. Several surgical and endovascular procedures have been described for resolving dehiscence. Within endovascular procedures, the sagittal sinus approach could be a technical alternative for tracking and accurate stent positioning within the sigmoid sinus when the jugular bulb anatomy is unfavorable. CASE PRESENTATION: A retrospective case series of three patients with pulsatile tinnitus due to sigmoid sinus wall dehiscence without intracranial hypertension was reviewed from January 2018 to January 2022. From the participants enrolled, the median age was 50.3 years (range 43-63), with 67% self-identifying as female and 33% as male. They self-identified as Hispanic. Sigmoid sinus dehiscence was diagnosed using angiotomography, and contralateral transverse sinus stenosis was observed in all patients. Patients underwent surgery via a navigated endovascular sagittal sinus approach for sigmoid sinus stenting. No neurological complications were associated with the procedure. Pulsatile tinnitus improved after the procedure in all patients. CONCLUSIONS: Superior sagittal sinus resection for sigmoid sinus wall stenting is a safe and effective technique. Pulsatile tinnitus due to sigmoid sinus wall dehiscence could be treated using the endovascular resurfacing stenting technique. However, further research is needed to evaluate the potential benefit of contralateral stenting for removing sinus dehiscence when venous stenosis is detected. However, resurfacing sigmoid sinus wall dehiscence results in symptomatic improvement.

Radiocirugía estereotáctica con acelerador lineal para el tratamiento de la neuralgia trigeminal. Experiencia de nueve años en una sola institución / Linear accelerator-based stereotactic radiosurgery for the treatment of trigeminal neuralgia. Nine years’ experience in a single institution

Introducción. El tratamiento farmacológico constituye el primer escalón terapéutico para el control del dolor en la neuralgia del trigémino, pero entre el 25-50% de los pacientes se hace farmacorresistente. Actualmente existen varias alternativas quirúrgicas para tratar a estos pacientes. Objetivo. Evaluar la efectividad y seguridad de la radiocirugía estereotáctica para el tratamiento de pacientes con neuralgia del trigémino. Pacientes y métodos. Se dio seguimiento a 30 pacientes que se sometieron a radiocirugía con acelerador lineal Novalis. Se calculó el 80% de la dosis en el isocentro, la zona de raíz de entrada del nervio trigémino. El tiempo medio de seguimiento fue de 27,5 meses (rango: 1-65 meses). Resultados. La edad media fue de 66 años (rango: 36-87 años), con un tiempo de evolución de 7,1 años (rango: 4-27 años). La distribución del dolor fue del lado derecho (63,3%). De los 30 pacientes, 27 tuvieron mejoría (90%) 1,6 meses (rango: 1 semana-4 meses) después del tratamiento; 10 pacientes (33,3%) tuvieron una valoración de grado I y 17 pacientes (56,6%) una valoración de grado II. Durante el seguimiento, cuatro pacientes (14,2%) tuvieron recidiva; dos se sometieron a reirradiación. El tiempo sin recurrencia fue de 62,7 meses (rango: 54,6-70,8 meses). La tasa de efectos secundarios fue del 76,7%, y sólo tres pacientes desarrollaron anestesia facial con pérdida del reflejo corneal. Conclusiones. El uso del acelerador lineal es una opción terapéutica efectiva en el tratamiento de la neuralgia del trigémino, proporciona a largo plazo adecuado control del dolor, reduce el uso de medicamentos y mejora la calidad de vida (AU)

Introduction. Pharmacological treatment is the first therapeutic step towards controlling pain in trigeminal neuralgia, but 25-50% of patients become medication resistant. There are currently several surgical alternatives for treating these patients. Aim. To evaluate the effectiveness and safety of stereotactic radiosurgery for the treatment of patients with trigeminal neuralgia. Patients and methods. A follow-up study was conducted on 30 patients who underwent radiosurgery using a Novalis linear accelerator. Eighty per cent of the dosage was calculated at the isocentre, the entry zone of the root of the trigeminal nerve. The mean follow-up time was 27.5 months (range: 1-65 months). Results. The mean age was 66 years (range: 36-87 years), with a time to progression of 7.1 years (range: 4-27 years). The distribution of the pain was from the right side (63.3%). Of the 30 patients, 27 experienced an improvement (90%) 1.6 months (range: 1 week-4 months) after the treatment; 10 patients (33.3%) scored grade I, and 17 patients (56.6%) obtained a score of grade II. During the follow-up, four patients (14.2%) suffered a relapse; two underwent re-irradiation. Time without recurrence was 62.7 months (range: 54.6-70.8 months). The rate of side effects was 76.7% and only three patients developed facial anaesthesia with loss of the corneal reflex. Conclusions. The use of the linear accelerator is an effective therapeutic option in the treatment of trigeminal neuralgia, since it provides adequate long-term control of the pain, reduces the use of medication and improves the quality of life (AU)